N/A
N=106
'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Chronic Hepatitis c
Bottom Line
View on ClinicalTrials.gov: NCT03088917 ↗Enrolled (actual)
106
Serious AEs
0.0%
Results posted
Feb 2020
Primary outcome: Primary: Liver Fibrosis Stage — 3; 1; 1 Participants
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Radboud University Medical Center
- Primary completion
- Dec 2019
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Liver Fibrosis Stage |
3; 1; 1 | — |
| SECONDARY Reasons for Loss to Follow-up |
2; 2; 5; 1 | — |
| SECONDARY Genotype Distribution |
2; 2; 1 | — |
| SECONDARY Fibrosis Progression |
2; 1 | — |
| SECONDARY Treatment Outcome |
2; 2; 1 | — |
Summary
Objective:
To coordinate active tracing of chronic hepatitis C patients lost to follow-up to inform them about there disease severity and treatment options.
Study design: This is a prospective cohort study, which will start as a pilot study in the Radboudumc Population: lost to follow-up chronic hepatitis C patients in the region Nijmegen. This so-called lost population consists of all patients, that in the past have been identified at the Radboudumc but who are currently lost to or have been withdrawn from follow-up. The time-span of interest will be 2000-2015. We estimate that this project will retrace 100 lost patients through this search.
Eligibility Criteria
Inclusion Criteria
- ever diagnosed with hepatitis C, lost to follow-up
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT03088917). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.